FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022096056> ?p ?o ?g. }

• W2022096056 endingPage "258" @default.
• W2022096056 startingPage "253" @default.
• W2022096056 abstract "Secondary hyperparathyroidism (SHPT) develops as a result of impaired calcium homeostasis when the failing kidneys disturb the complicated interactions between parathyroid hormone (PTH), calcium, phosphorus, and vitamin D. Twelve years ago, the calcium-sensing receptor (CaR) of the parathyroid gland was first cloned and identified as the principal regulator of PTH secretion. The activation of the CaR by small changes in extracellular calcium (ec(Ca2+)) regulates PTH, calcitonin secretion, urinary calcium excretion, and ultimately, bone turnover. The CaR became an ideal target for the development of calcimimetics, which are able to amplify its sensitivity to ec(Ca2+) suppressing PTH secretion. Cinacalcet HCl, a first-in-class calcimimetic, approved in both the United States and the European Union, offers a new therapeutic approach to the treatment of SHPT. The efficacy of cinacalcet HCl in treating SHPT in dialysis patients (n = 1,136) was studied in three similarly designed phase III clinical trials comparing patients receiving standard SHPT therapy plus cinacalcet HCl or plus placebo. Cinacalcet HCl, dosed from 30 to 180 mg/day, significantly reduced PTH while simultaneously lowering calcium, phosphorus, and calcium-phosphorus product in each of the three studies. Respective to the National Kidney Foundation-Kidney Disease Outcomes and Quality Initiative (NKF-K/DOQI) recommended targets for bone and mineral metabolism, 41% of cinacalcet HCl-treated patients achieved both PTH and calcium-phosphorus product targets, compared with only 6% in the placebo group. Results from 2 recent phase IIIb studies (TARGET and CONTROL) conducted in the United States also showed that cinacalcet HCl can significantly reduce or maintain reduction in PTH while simultaneously lowering calcium, phosphorus, and calcium-phosphorus product. In addition, patients taking vitamin D at baseline of these 2 trials were able to see significant mean reductions in vitamin D dose. Further assessment of cinacalcet HCl trial data has shown some important effects in SHPT patient clinical outcomes. A combined post-hoc analysis of clinical events using data from 4 (n = 1,184) cinacalcet HCl phase II and III studies suggests that treatment with cinacalcet HCl has a beneficial effect on relative risks of parathyroidectomy, fracture, and hospitalization for cardiovascular complications. Nausea and vomiting occurred more often in patients taking cinacalcet HCl than in those taking a placebo. There were also transient episodes of hypocalcemia in 5% of cinacalcet HCl patients versus 1% of placebo patients. However, these episodes were rarely associated with symptoms. The development of calcimimetics has already changed the treatment of SHPT in renal patients. Its effectiveness on the control of PTH secretion, along with simultaneous reductions in calcium, phosphorus, and calcium-phosphorus product, give this agent an advantage over traditional therapies in all levels of severity of SHPT." @default.
• W2022096056 created "2016-06-24" @default.
• W2022096056 creator A5078942933 @default.
• W2022096056 date "2006-07-01" @default.
• W2022096056 modified "2023-10-15" @default.
• W2022096056 title "Cinacalcet HCl: A Novel Treatment for Secondary Hyperparathyroidism Caused by Chronic Kidney Disease" @default.
• W2022096056 cites W1566173290 @default.
• W2022096056 cites W1963611706 @default.
• W2022096056 cites W1973835767 @default.
• W2022096056 cites W1975747275 @default.
• W2022096056 cites W1989640819 @default.
• W2022096056 cites W1991041088 @default.
• W2022096056 cites W1997008150 @default.
• W2022096056 cites W2009441758 @default.
• W2022096056 cites W2023883454 @default.
• W2022096056 cites W2031455439 @default.
• W2022096056 cites W2042639382 @default.
• W2022096056 cites W2048614102 @default.
• W2022096056 cites W2054323843 @default.
• W2022096056 cites W2077131998 @default.
• W2022096056 cites W2079403425 @default.
• W2022096056 cites W2081227689 @default.
• W2022096056 cites W2084263498 @default.
• W2022096056 cites W2086766564 @default.
• W2022096056 cites W2086883857 @default.
• W2022096056 cites W2096388640 @default.
• W2022096056 cites W2097417649 @default.
• W2022096056 cites W2102288319 @default.
• W2022096056 cites W2105407962 @default.
• W2022096056 cites W2114164409 @default.
• W2022096056 cites W2121613126 @default.
• W2022096056 cites W2127560186 @default.
• W2022096056 cites W2132817664 @default.
• W2022096056 cites W2141805222 @default.
• W2022096056 cites W2144419439 @default.
• W2022096056 cites W2150677313 @default.
• W2022096056 cites W2152542082 @default.
• W2022096056 cites W2161698416 @default.
• W2022096056 cites W4241857953 @default.
• W2022096056 cites W4248963745 @default.
• W2022096056 cites W4253293013 @default.
• W2022096056 cites W4254079664 @default.
• W2022096056 doi "https://doi.org/10.1053/j.jrn.2006.04.010" @default.
• W2022096056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16825031" @default.
• W2022096056 hasPublicationYear "2006" @default.
• W2022096056 type Work @default.
• W2022096056 sameAs 2022096056 @default.
• W2022096056 citedByCount "65" @default.
• W2022096056 countsByYear W20220960562012 @default.
• W2022096056 countsByYear W20220960562013 @default.
• W2022096056 countsByYear W20220960562014 @default.
• W2022096056 countsByYear W20220960562015 @default.
• W2022096056 countsByYear W20220960562016 @default.
• W2022096056 countsByYear W20220960562017 @default.
• W2022096056 countsByYear W20220960562018 @default.
• W2022096056 countsByYear W20220960562019 @default.
• W2022096056 countsByYear W20220960562020 @default.
• W2022096056 countsByYear W20220960562021 @default.
• W2022096056 countsByYear W20220960562022 @default.
• W2022096056 countsByYear W20220960562023 @default.
• W2022096056 crossrefType "journal-article" @default.
• W2022096056 hasAuthorship W2022096056A5078942933 @default.
• W2022096056 hasConcept C126322002 @default.
• W2022096056 hasConcept C134018914 @default.
• W2022096056 hasConcept C170033053 @default.
• W2022096056 hasConcept C2775945674 @default.
• W2022096056 hasConcept C2778653478 @default.
• W2022096056 hasConcept C2778838027 @default.
• W2022096056 hasConcept C2780280601 @default.
• W2022096056 hasConcept C2780534505 @default.
• W2022096056 hasConcept C2781208988 @default.
• W2022096056 hasConcept C519063684 @default.
• W2022096056 hasConcept C71924100 @default.
• W2022096056 hasConcept C87975464 @default.
• W2022096056 hasConceptScore W2022096056C126322002 @default.
• W2022096056 hasConceptScore W2022096056C134018914 @default.
• W2022096056 hasConceptScore W2022096056C170033053 @default.
• W2022096056 hasConceptScore W2022096056C2775945674 @default.
• W2022096056 hasConceptScore W2022096056C2778653478 @default.
• W2022096056 hasConceptScore W2022096056C2778838027 @default.
• W2022096056 hasConceptScore W2022096056C2780280601 @default.
• W2022096056 hasConceptScore W2022096056C2780534505 @default.
• W2022096056 hasConceptScore W2022096056C2781208988 @default.
• W2022096056 hasConceptScore W2022096056C519063684 @default.
• W2022096056 hasConceptScore W2022096056C71924100 @default.
• W2022096056 hasConceptScore W2022096056C87975464 @default.
• W2022096056 hasIssue "3" @default.
• W2022096056 hasLocation W20220960561 @default.
• W2022096056 hasLocation W20220960562 @default.
• W2022096056 hasOpenAccess W2022096056 @default.
• W2022096056 hasPrimaryLocation W20220960561 @default.
• W2022096056 hasRelatedWork W1860370092 @default.
• W2022096056 hasRelatedWork W1973835767 @default.
• W2022096056 hasRelatedWork W2028755123 @default.
• W2022096056 hasRelatedWork W2077900736 @default.
• W2022096056 hasRelatedWork W2110396401 @default.
• W2022096056 hasRelatedWork W2341064820 @default.
• W2022096056 hasRelatedWork W2405448469 @default.

• next